INTRODUCTION Docetaxel use was first found to prolong overall survival (OS) in patients with metastatic castration-resistant prostate cancer.1, 2 Subsequently, docetaxel use was studied in the metastatic castration-sensitive prostate cancer (mCSPC) setting, and found to prolong OS in patients with high-volume metastatic disease when added to the standard of care (SOC) at the time of androgen deprivation therapy (ADT).3, 4 Later, on the basis of the results of two randomized trials, six cycles...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Johnathan
Contact Johnathan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack